Tandem Diabetes (NASDAQ: TNDM) reported Q1 EPS of ($0.83), $0.04 worse than the analyst estimate of ($0.79). Revenue for the quarter came in at $12.3 million versus the consensus estimate of $12.19 million. Tandem Diabetes reaffirmed FY2015 guidance.

For the year ending December 31, 2015, the Company affirms its prior guidance as follows:

• Sales are estimated to be in the range of $70.0 million to $75.0 million, which includes $1.0 million to $3.0 million of t:flex Insulin Pump sales
• Operating margin is estimated to be in the range of negative 100 percent to negative 110 percent, which includes approximately $13.0 million to $14.0 million in non-cash, stock-based compensation expense

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.